Abstract
Improved remission rates of 70%–80% in childhood acute nonlymphocytic leukemia (ANLL) have been achieved by several groups. Anthracyclines (daunorubicin, doxorubicin) are of great value in the treatment of ANLL. Protocols effective for ANLL commonly include combinations with cytosine arabinoside [1–3]. Aclarubicin, a new alternative anthracycline antibiotic, has proven efficacy in relapsed or advanced as well as in untreated ANLL in adults [4–6]. In 1984 a cooperative multicenter study (AML-IGCI-84) was initiated which incorporated aclarubicin in the first-line therapy of previously untreated childhood ANLL.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
